You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Merck
Johnson and Johnson
Express Scripts

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,188,811

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,188,811 protect, and when does it expire?

Patent 10,188,811 protects QNASL and is included in one NDA.

This patent has forty-five patent family members in twenty-nine countries.

Summary for Patent: 10,188,811
Title:Nasal spray device
Abstract: A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.
Inventor(s): Zeng; Xian-Ming (Miami, FL), Walsh; Declan (Co. Kilkenny, IE), Ly; Jade Ching-Ying (Miami, FL), Morales; Armando (Miami, FL)
Assignee: TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. (Horsham, PA) IVAX PHARMACEUTICALS IRELAND (Waterford, IE)
Application Number:14/865,823
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Device;

Drugs Protected by US Patent 10,188,811

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-002 Dec 17, 2014 RX Yes No   Start Trial   Start Trial Y   Start Trial
Teva Branded Pharm QNASL beclomethasone dipropionate AEROSOL, METERED;NASAL 202813-001 Mar 23, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Johnson and Johnson
McKesson
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.